Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2008
12/31/2008WO2009000085A1 Quinoline and quinazoline derivatives useful as modulators of gated ion channels
12/31/2008WO2009000038A1 Combination methods and compositions for treatment of neuropathic pain
12/31/2008WO2009000023A1 Method for optimizing the treatment of chronic myeloid leukemia with abl tyrosine kinase inhibitors
12/31/2008WO2008141097A3 Stereoisomers propofol therapeutic compounds
12/31/2008WO2008141012A3 Quaternary alkyl ammonium bacterial efflux pump inhibitors and therapeutic uses thereof
12/31/2008WO2008140507A3 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
12/31/2008WO2008140066A3 Pyridone derivatives as p38a mapk inhibitors
12/31/2008WO2008138089A3 Pharmaceutical composition comprising a local anaesthetic and a carboxyvinyl polymer
12/31/2008WO2008137490A3 Systemic insulin-like growth factor-1 therapy reduces diabetic peripheral neuropathy and improves renal function in diabetic nephropathy
12/31/2008WO2008136705A3 Drugs for treating and preventing benign prostatic hyperplasia, prostatitis, impotency, infertility and prostate cancer and a method for the use thereof
12/31/2008WO2008135525A3 Substituted azetidines, manufacturing and use thereof as medicaments
12/31/2008WO2008133669A3 Viral inhibitors
12/31/2008WO2008133664A3 Carboranylporphyrins and uses thereof
12/31/2008WO2008132541A3 Conjugates of 2-fluoro-2-deoxy-glucose and their uses as anti cancer agents
12/31/2008WO2008132139A3 New heterocyclic derivatives useful for the treatment of cns disorders
12/31/2008WO2008132138A9 Derivatives of 4,6-disubstituted aminopyrimidines
12/31/2008WO2008132138A8 Derivatives of 4,6-disubstituted aminopyrimidines
12/31/2008WO2008131354A3 Phytoestrogens as regulators of hedgehog signaling and methods of their use in cancer treatment
12/31/2008WO2008129288A3 Disulfonamides useful in the treatment of inflammation
12/31/2008WO2008129157A3 Amorphous solid composition containing a pyrazole-3-carboxamide in amorphous form and stabilising carriers
12/31/2008WO2008128072A3 Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
12/31/2008WO2008127399A3 Azaindole derivatives as cftr modulators
12/31/2008WO2008126034A3 Oxazolidinone antibiotics
12/31/2008WO2008123796A3 Substituted 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indoles, methods for the production and use thereof
12/31/2008WO2008122897A3 Paraben compounds
12/31/2008WO2008122798A3 Pharmaceutical composition of an eg5 inhibitor and a microtubule interfering agent for the treatment of cancer
12/31/2008WO2008122767A3 2, 6, 9-substituted purine derivatives having anti proliferative properties
12/31/2008WO2008121877A3 Cftr inhibitor compounds and uses thereof
12/31/2008WO2008121386A3 Calcimimetic compounds for use in the treatment of bowel disorders
12/31/2008WO2008120214A3 Compositions containing phosphatidylserine in treating diabetes associated conditions
12/31/2008WO2008120070A3 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) displaying hepatoprotective, hypoammoniemic and detoxic action, a method for its production and a pharmaceutical composition based thereon
12/31/2008WO2008117269A3 Heterotri cyciii c compounds as serotonergic and/or dopaminergic agents and uses thereof
12/31/2008WO2008117241A3 Thiazolidine derivatives as orexin receptor antagonists
12/31/2008WO2008116024A3 Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
12/31/2008WO2008113862A3 Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
12/31/2008WO2008109493B1 Nucleic acid compounds for inhibiting cd19 gene expression and uses thereof
12/31/2008WO2008109493A4 Nucleic acid compounds for inhibiting cd19 gene expression and uses thereof
12/31/2008WO2008109379A9 Nucleic acid compounds for inhibiting il17a gene expression and uses thereof
12/31/2008WO2008109364B1 Nucleic acid compounds for inhibiting frap1 gene expression and uses thereof
12/31/2008WO2008109364A4 Nucleic acid compounds for inhibiting frap1 gene expression and uses thereof
12/31/2008WO2008103276A3 Compositions and methods for potentiated activity of biologicaly active molecules
12/31/2008WO2008099278A3 Pharmaceutical compositions and methods for ccr5 antagonists
12/31/2008WO2008097623A3 Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy
12/31/2008WO2008089388A3 Treatment of cancers having resistance to chemotherapeutic agents
12/31/2008WO2008086400A3 Sirtuin-activating compounds of enhanced bioavailability
12/31/2008WO2008082692A9 Isothiocyanate compounds, pharmaceutical compositions, and uses thereof
12/31/2008WO2008082487A3 Novel jnk inhibitors
12/31/2008WO2008079328A3 Omega-5-fatty acids useful in lipoxygenase 5 inhibition and in the treatment of cancer
12/31/2008WO2008070132A3 Methods of use of trk receptor modulators
12/31/2008WO2008068777A3 Stable lercanidipine formulation
12/31/2008WO2008068727A3 Pharmaceutical composition comprising candesartan cilexetil
12/31/2008WO2008067060A8 Formulations for treatment of adipose tissue, cutaneous tissue and disorders, and muscular tissue
12/31/2008WO2008063556A3 Nornicotine for the treatment of pain
12/31/2008WO2008060375A3 Upregulating bdnf levels to mitigate mental retardation
12/31/2008WO2008060332A3 Methods for treating or reducing muscle fatigue
12/31/2008WO2008057859A3 Modulators of glucocorticoid receptor, ap-i and/or nf-kappab activity and use thereof
12/31/2008WO2008054767A9 N4 modifications of pyrimidine analogs and uses thereof
12/31/2008WO2008040995A9 Indazoles for use as dpp-iv inhibitors
12/31/2008WO2008039980A3 Apoptotic cell-mediated transfection of mammalian cells with interfering rna
12/31/2008WO2008037421A3 Pharmaceutical compositions comprising an s1p modulator
12/31/2008WO2008027880A3 Strontium-based treatment of otosclerosis
12/31/2008WO2008024499A3 Methods for in vivo identification of endogenous mrna targets of micrornas
12/31/2008WO2008024481A3 3,4-dihydro-2 (1h) - quinolinone and 2 (1h)-quinolinone derivatives
12/31/2008WO2008023278A8 1alpha-hydroxy-2- (3 ' -hydroxypropylidene) -19-n0r- vitamin d compounds with a 1,1-dimethylpropyl side chain
12/31/2008WO2008022060A3 Imidazo-pyridine derivatives for modulating protein kinase activity
12/31/2008WO2008021394A3 Pharmaceutical formulations of cannabinoids and method of use
12/31/2008WO2008021049A3 Crystalline antifungal compounds
12/31/2008WO2008016738A3 Antibacterial agents and related screening methods using small molecule macroarrays
12/31/2008WO2008016711A3 Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives
12/31/2008WO2008014381A3 Modulators of chemokine receptor activity, crystalline forms and process
12/31/2008WO2008014360A3 Modulators of chemokine receptor activity, crystalline forms and process
12/31/2008WO2008011406A3 Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
12/31/2008WO2008003978A3 Dioxo-alkanes and dioxo-alkenes
12/31/2008WO2007147117A3 Methods of reducing or eliminating salmonella in reptiles and/or their eggs
12/31/2008WO2007144902A8 Chewable bilayer tablet formulation
12/31/2008WO2007133560A3 Acetylenic heteroaryl compounds
12/31/2008WO2007131689A3 Pharmaceutical combinations comprising a mtor inhibitor and a raf kinase inhibitor
12/31/2008WO2007117778A8 Quinolones useful as inducible nitric oxide synthase inhibitors
12/31/2008WO2007103740A3 Immunoassays, haptens, immunogens and antibodies for anti-hiv therapeutics
12/31/2008WO2007077561A3 Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
12/31/2008WO2007075801A3 Method and system for the delivery of corticosteroids having an enhanced pharmacokinetic profile
12/31/2008WO2007070598A8 Nucleotide and oligonucleotide prodrugs
12/31/2008WO2007012947A3 Method of treating ischemia-reperfusion injury
12/31/2008WO2006111960A3 Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
12/31/2008WO2006078753B1 N-substituted heterocyclic sulfonamides
12/31/2008WO2006078753A4 N-substituted heterocyclic sulfonamides
12/31/2008WO2006041900A9 SUBSTITUTED N-ARYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS
12/31/2008WO2006041900A8 SUBSTITUTED N-ARYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS
12/31/2008WO2005066173A3 Processes for the preparation of substituted azetidinone
12/31/2008EP2009100A1 siRNA SPECIFIC TO WT1 17AA(-)ISOFORM AND USE THEREOF
12/31/2008EP2009042A1 Anion-binding polymers and uses thereof
12/31/2008EP2009031A2 Antimicrobial Compositions and methods of making same
12/31/2008EP2009024A1 Glucagon-like peptide-2 analogs
12/31/2008EP2009018A2 T cell antigen receptor peptides
12/31/2008EP2009012A1 Novel compound having heterocyclic ring
12/31/2008EP2009011A1 Nitrogen-containing heterocyclic compound
12/31/2008EP2009010A1 Cocrystal of c-glycoside derivative and l-proline
12/31/2008EP2009009A1 Crystalline antifungal compounds
12/31/2008EP2009008A1 Imatinib base, and imatinib mesylate and processes for preparation thereof
12/31/2008EP2009007A1 Plant-derived therapeutic agent for malignant tumor
1 ... 2926 2927 2928 2929 2930 2931 2932 2933 2934 2935 2936 2937 2938 2939 2940 2941 2942 2943 2944 2945 2946 ... 7860